Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation最新文献

{"title":"Symptomatic Changes Associated With a Pharmacist-Led COPD Program.","authors":"Edward C Portillo, Steven Do, Scott Hetzel, Jennifer Nguyen, Katelynn Cleveland, Cara Ray, Jenna Vande Hey, Pramit Maskey, Rena Steiger-Chadwick, Lucas M Donovan, Dylan Erdelt, Sarah Will, Michael Shawn McFarland, Heather Ourth, Michelle Chui","doi":"10.15326/jcopdf.2025.0716","DOIUrl":"10.15326/jcopdf.2025.0716","url":null,"abstract":"","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Pulmonary Artery and Vein Volumes Independently Predict Oxygen Desaturation in Smokers.","authors":"Anastasia K A L Kwee, Wouter A C van Amsterdam, Firdaus A A Mohamed Hoesein, Leticia Gallardo-Estrella, Jean-Paul Charbonnier, Stephen M Humphries, Harm A W M Tiddens, James D Crapo, Richard Casaburi, Pim A de Jong, David A Lynch, Esther Pompe","doi":"10.15326/jcopdf.2025.0694","DOIUrl":"10.15326/jcopdf.2025.0694","url":null,"abstract":"<p><strong>Background and research question: </strong>Multiple factors affect oxygen levels in chronic obstructive pulmonary disease (COPD), including airflow limitation, emphysema, ventilation-perfusion mismatch, cardiac dysfunction and pulmonary vascular remodeling. We investigated the association of small pulmonary vein and artery volume with oxygen saturation.</p><p><strong>Methods: </strong>In the COPDGene cohort, current and former smokers were characterized with questionnaires, spirometry, oxygen saturation measurements and computed tomography (CT). On CT scans, small pulmonary vein and artery volume (diameter<1mm) were quantified with automated image analysis. Associations of small vein and artery volume with oxygen saturation and supplemental oxygen use were investigated with multivariable regression, correcting for body surface area, clinical (including emphysema, FEV₁%predicted, coronary calcium) and technical covariates.</p><p><strong>Results: </strong>8931 subjects were included with a mean age of 60.0±9.0 years. 52.7% were male. Half were current smokers (50.7%); number of pack-years was 44.5±25.0. Median saturation was 97% (IQR 95-98%), 1040 (11.6%) subjects used supplemental oxygen. Oxygen saturation decreased with 0.14% [-0.25,-0.03] (p=0.01) for 1 mL/m² each increase in vein volume and 0.15% [-0.21, -0.09] for artery volume. Oxygen users had higher small vein volume (3.01±0.61 mL/m²) compared to those without oxygen (2.68±0.53 mL/m²). Each 1 mL/m² increase in vein volume (adjusted OR 1.51[1.25,1.84] p<0.001) and artery volume (OR 1.16[1.02, 1.31]) was associated with more supplemental oxygen use.</p><p><strong>Interpretation: </strong>In current and former smokers, higher small pulmonary vein and artery volume were associated with lower resting saturation and more supplemental oxygen use, independent of lung disease severity or technical parameters. This suggests a role for vascular remodeling in smoking-related disease.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of Reduced Forced Expiratory Volume in 3 Seconds to Forced Expiratory Volume in 6 Seconds in Adults.","authors":"Siman Liao, Juncheng Liang, Jie Ou, Ranxi Peng, Shiyu Zhang, Leheng Tang, Qiaorui Zhou, Yingtong Chen, Xiaozi Guo, Jingxian Chen, Qi Wan, Zihui Wang, Zhishan Deng, Yumin Zhou, Fan Wu","doi":"10.15326/jcopdf.2025.0649","DOIUrl":"https://doi.org/10.15326/jcopdf.2025.0649","url":null,"abstract":"<p><strong>Background: </strong>The forced expiratory volume (FEV) in 3 seconds (FEV₃) to FEV₆ ratio (FEV₃/FEV₆) is a novel spirometry measure that identifies early airflow abnormalities, but its long-term prognosis value in the general population remains unclear. We aim to evaluated the long-term all-cause mortality risk among participants with reduced FEV₃/FEV₆.</p><p><strong>Methods: </strong>Data were obtained from the National Health and Nutrition Examination Survey cycles 1988-1994 and 2007-2012 Reduced FEV₃/FEV₆ was defined as FEV₃/FEV₆ less than the lower limit of normal. Multivariable logistic regression was used to assess the relationship of reduced FEV₃/FEV₆ with comorbidities and chronic respiratory symptoms. The relationship between reduced FEV₃/FEV₆ and all-cause mortality was evaluated using Cox regression models. The non-linear relationship between FEV₃/FEV₆ and all-cause mortality was assessed using restricted cubic splines. Subgroup analyses and sensitivity analyses were conducted to validate the robustness of the relationship.</p><p><strong>Results: </strong>Overall, 25,159 participants were enrolled in the 308-month median follow-up analysis, of whom 8.8% (2,225/25,159) had reduced FEV₃/FEV₆ Participants with reduced FEV₃/FEV₆ exhibited increased risks of congestive heart failure, asthma, chronic bronchitis, emphysema, respiratory symptoms, and all-cause mortality risk (hazard ratio=1.23, 95% confidence interval: 1.13-1.34, P<0.001). The findings remained consistent across subgroups. A non-linear U-shaped association was observed between FEV₃/FEV₆ and all-cause mortality, with the turning point at 1.04, and sensitivity analyses confirmed the robustness of this relationship.</p><p><strong>Conclusion: </strong>Participants with reduced FEV₃/FEV₆ had worse respiratory health outcomes, suggesting that FEV₃/FEV₆ can be used as prognostic spirometry indicator.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering Vitamin D Supplementation in Pulmonary Disease: The Case for Targeted Respiratory Delivery.","authors":"Kevin D Schichlein, Ilona Jaspers, M Bradley Drummond","doi":"10.15326/jcopdf.2025.0713","DOIUrl":"https://doi.org/10.15326/jcopdf.2025.0713","url":null,"abstract":"<p><p>Despite compelling epidemiological evidence linking vitamin D deficiency to adverse outcomes in chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, randomized controlled trials have consistently failed to demonstrate clinically meaningful benefits from oral vitamin D supplementation. This disconnect between observational associations and interventional evidence represents a significant paradox in pulmonary medicine. Recent meta-analyses have found limited protective or therapeutic effects of oral supplementation on exacerbation rates, lung function, hospitalizations, or quality of life measures. We propose that this therapeutic failure reflects not a lack of vitamin D's efficacy but rather a fundamental limitation in the route of delivery. Oral vitamin D supplementation undergoes hepatic metabolism and systemic dilution before reaching respiratory tissues. High expression of CYP24A1, the vitamin D-inactivating enzyme, in pulmonary vasculature suggests that orally delivered vitamin D may be degraded before reaching the lung lumen. The respiratory epithelium possesses complete machinery for vitamin D activation, and vitamin D receptors are expressed throughout airway epithelial and immune cells, making direct pulmonary delivery mechanistically feasible. Pre-clinical studies demonstrate that nebulized or inhaled vitamin D reduces inflammation, protects epithelial barrier function, and improves lung function in murine models of respiratory disease without producing off-target systemic effects or hypercalcemia. Direct lung delivery of vitamin D represents an unexplored therapeutic strategy that could transform management of chronic respiratory diseases, like COPD, by achieving local therapeutic concentrations while minimizing systemic exposure. Clinical trials investigating safety, dosing optimization, and efficacy are warranted.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Health Care Resource Utilization Among Individuals Undergoing Alpha-1 Antitrypsin Testing in a Quaternary Health System.","authors":"Drew D Robinson, Chia-Ying Chiu, Jane I Hampton, George M Solomon, J Michael Wells","doi":"10.15326/jcopdf.2025.0723","DOIUrl":"https://doi.org/10.15326/jcopdf.2025.0723","url":null,"abstract":"<p><strong>Rationale: </strong>Alpha-1 antitrypsin deficiency (AATD) is a genetically inherited condition that can result in serious lung and liver disease. It is unclear whether testing for common alleles is sufficient or if testing for rare variants is helpful in identifying clinically significant disease.</p><p><strong>Methods: </strong>A retrospective review was performed on adult patients who had AAT phenotyping from January 2016 through December 2021. We recorded clinical characteristics and then grouped patients based on PI*types: Normal, PI*Z-heterozygotes (het), PI*ZZ, PI*S-hets, and defined a PI*Non-S/Non-Z group to include other identified PI*types. Chi Square and Kruskal-Wallis tests were used for bivariate analyses, generalized linear models for modeling forced expiratory volume in 1-second (FEV1), and logistic regression modeling for healthcare utilization outcomes adjusted for race, age, and sex.</p><p><strong>Results: </strong>1,772 tests were ordered from January 2016 through December 2021. Testing identified 79.5% Pi*MM, 8.4% PI*Z-het, 8.4% Pi*S-het, 3.3% PI*Non-S/Non-Z, and 0.5% PI*ZZ. FEV1 to forced vital capacity (FEV1/FVC) and FEV1 percent predicted were lowest in the PI*Non-S/Non-Z group compared to the other groups. PI*Non-S/Non-Z group had higher mean neutrophil lymphocyte ratio (NLR) compared to the other groups (p=0.021), higher hospitalization for acute respiratory events (27.6%; p=0.019), ICU utilization (15.3%, p=0.011) and death (25.4%, p=0.041) compared to the other groups.</p><p><strong>Conclusion: </strong>AATD PI*typing identified several allelic combinations not previously linked with clinical disease. Compared to other PI*type groups, PI*'Non-S/Non-Z' group had impairments in pulmonary function, elevated inflammatory markers, higher health care utilization, and death. Our results underpin the need to explore relationships between rare allelic combinations and clinical outcomes.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding COPD Patients' Perspectives on Utilizing Strategies to Limit Their Exposure to Wildfire Smoke.","authors":"Jimmy Yao, Caitlin M Lydon, Nina Pak, Kathleen A Daly, Mary Meyer, Nadia Hansel, Mark T Dransfield, Stacey Alexeeff, Andrea Altshuler, Laura C Myers","doi":"10.15326/jcopdf.2025.0682","DOIUrl":"https://doi.org/10.15326/jcopdf.2025.0682","url":null,"abstract":"<p><strong>Background: </strong>A translation gap exists in how patients with chronic obstructive pulmonary disease (COPD) utilize mitigation strategies to limit exposure to wildfire smoke. This study examines patients' point of view about barriers and facilitators of strategy uptake.</p><p><strong>Methods: </strong>We performed semi-structured, virtual interviews with members of Kaiser Permanente Northern California until thematic saturation. We recruited participants aged ≥65 in the lowest quartile of socioeconomic status because they are disproportionately exposed to air pollution with fewer resources to mitigate exposure. Qualitative analysis was performed using inductive and deductive approaches.</p><p><strong>Results: </strong>Of 90,696 adults, we interviewed 31 in January 2025. Participants were racially and ethnically diverse (19% Black, 10% Hispanic, 3% Native American, 68% non-Hispanic White), from 10 counties. Three major themes were 1) patients tended to get wildfire and air quality information from internet and smartphone apps, not clinical encounters, but expressed openness to receiving information from clinicians, 2) there appear to be modifiable barriers to uptake of mitigation strategies, such as education and supplying equipment (e.g., masks, air cleaners), and 3) patients prefer real-time alerts sent to their phones from trusted sources, such as healthcare entities, to change their behavior during periods of poor air quality.</p><p><strong>Conclusion: </strong>By understanding patients' perspectives about their relationship with wildfire smoke, we've gained practical information to begin designing interventions to protect patients' health during periods of poor air quality.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Impact of Financial Toxicity in COPD: A Qualitative Study.","authors":"Sonal G Mallya, Kaila Holloway, Cyd K Eaton, Michelle Sharp, Nirupama Putcha, Kristin A Riekert, Theodore J Iwashyna, Michelle N Eakin","doi":"10.15326/jcopdf.2025.0712","DOIUrl":"https://doi.org/10.15326/jcopdf.2025.0712","url":null,"abstract":"<p><strong>Background: </strong>Individuals with chronic obstructive pulmonary disease (COPD) often face direct and indirect medical costs from unplanned ED visits and hospitalizations for acute exacerbations, out-of-pocket expenses for inhaled bronchodilators, and income loss from disability. Yet financial toxicity, which describes the objective burden and subjective distress resulting from medical costs, has not been studied in COPD. Individual experiences of financial toxicity in COPD offer insight into challenges that may be unique to this population.</p><p><strong>Methods: </strong>We conducted semi-structured interviews with 30 purposively sampled individuals with physician-diagnosed COPD. Transcripts were analyzed using inductive coding by 2 independent coders, and codes and were categorized through thematic analysis.</p><p><strong>Results: </strong>Thirty participants completed semi-structured interviews, of whom 56% were women, 43% non-Hispanic White, and 43% non-Hispanic Black. The mean age was 69.5 years, and 24 (70%) had public health insurance only. Several themes emerged including: (1) the sources of material burden in COPD; (2) adjustments to disease management, such as medication nonadherence or foregoing treatments; (3) adjustments to financial planning, including both changes to day-to-day spending and disruptions in major financial plans; (4) emotional impact; and (5) communication with healthcare providers.</p><p><strong>Conclusion: </strong>Our findings are the first, to our knowledge, to describe the impact of financial toxicity in individuals with COPD. Financial toxicity in COPD is common and may adversely impact disease self-management, financial self-management, and psychological wellbeing.Additional research is needed to examine its impact on patient-reported outcomes and to develop interventions to reduce its burden.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada.","authors":"Mohit Bhutani, Alan Kaplan, Sheena Kayaniyil, Kyla Jamieson, Ross Ormsby, John Bell, Prachi Bhatt, Jennifer Carioto, Bruce Pyenson","doi":"10.15326/jcopdf.2025.0687","DOIUrl":"https://doi.org/10.15326/jcopdf.2025.0687","url":null,"abstract":"<p><strong>Background: </strong>Chronic Obstructive Pulmonary Disorder (COPD) is the fifth leading cause of death in Canada. The ETHOS (NCT02465567) and IMPACT randomized controlled trials (RCT) (NCT02164513) demonstrated reduced exacerbations and all-cause mortality for patients with COPD on single-inhaler triple therapy (SITT). The 2023 Canadian Thoracic Society (CTS) COPD Pharmacotherapy guidelines recommend triple therapy and preferably SITT use in patients with moderate/severe symptom burden and high future risk of exacerbations. The clinical impact of broader SITT use in Canada has not yet been studied.</p><p><strong>Aim: </strong>To estimate the benefit of appropriate SITT use according to CTS COPD guidelines on mortality, exacerbations and their corresponding costs in Canada.</p><p><strong>Methods: </strong>A stochastic model using literature-derived characteristics (e.g. incidence, changes in COPD severity, treatment, mortality, and exacerbations) simulated the Canadian COPD population. Patients were assigned % of FEV₁ predicted levels and their annual characteristics were modeled for 2025-2034 under 2 scenarios: \"status quo\" (current practice) and \"increased SITT\" (following CTS guidelines).</p><p><strong>Results: </strong>Based on our simulated results for the flagged population, \"Increased SITT\" use over 10 years compared to current treatment reduced moderate and severe exacerbation rates by 23% and 12%, respectively, for a reduction of 159,000 severe and 2.81 million moderate exacerbations and reduced all-cause mortality rate by 22%. In the flagged population alone, this reduction in exacerbations would equate to a savings of CA$3.9 billion over 10 years.</p><p><strong>Conclusion: </strong>Appropriate use of SITT informed by the 2023 CTS COPD guidelines could lower mortality, exacerbation frequency and their corresponding costs in patients with COPD.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Bleeding Risks and All-Cause Death Between Warfarin and Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Obstructive Pulmonary Disease: A Multicenter Retrospective Cohort Study","authors":"Na Zhao, Ting Wei, Xinhai Huang, Guilan Wu, Ruijuan Li, Qiaowei Zheng, Xiumei Liu, Hengfen Dai, Xiangsheng Lin, Yuxin Liu, Jun Su, Xiaomin Dong, Cuifang You, Shuzheng Jiang, Yanxian Lan, Jinhua Zhang","doi":"10.15326/jcopdf.2025.0648","DOIUrl":"10.15326/jcopdf.2025.0648","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) may influence bleeding in atrial fibrillation (AF). We evaluated bleeding and all-cause death risks under warfarin versus direct oral anticoagulants (DOACs).</p><p><strong>Methods: </strong>Based on a retrospective cohort from 12 centers of patients with AF on oral anticoagulation, we evaluated the associations of COPD and anticoagulant class with clinical outcomes using overlap-weighted logistic regression. Prespecified sensitivity and subgroup analyses were performed.</p><p><strong>Results: </strong>COPD was associated with higher bleeding risk only among patients treated with warfarin (total bleeding: odds ratio [OR] 2.53, 95% confidence interval [CI] 1.00–6.45; risk difference [RD] 9.05%, 95% CI 0.15%–22.50%; minor bleeding: OR 3.00, 95% CI 1.09–8.24; RD 8.53%, 95% CI 0.56%–21.53%). Among patients with AF and COPD, DOACs were associated with reduced risks of total bleeding (OR 0.08, 95% CI 0.01–0.50; RD –8.4%, 95% CI -22.0% to -5.3%) and minor bleeding (OR 0.01; RD -9.5%, 95% CI -23.1% to -4.5%) compared with warfarin.\u0000Subgroup analyses suggested that DOACs were associated with increased mortality at estimated glomerular filtration rate (eGFR) ≥60mL/min/1.73m² (OR 3.07, 95% CI 0.78–12.03; RD 9.9%) but lower mortality at eGFR <60mL/min/1.73m² (OR 0.20, 95% CI 0.05–0.78; RD -24.1%). Factor Xa inhibitors were associated with a higher major bleeding risk compared with dabigatran (OR 4.56, 95% CI 1.70–12.26; RD 10.2%, 95% CI 0.2%–20.1%; with a number needed to harm of 10).</p><p><strong>Conclusion: </strong>In AF with comorbid COPD, DOACs minimize bleeding versus warfarin and may confer survival benefit in renal impairment. Differential bleeding risk should be considered when choosing among DOACs.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":"93-103"},"PeriodicalIF":2.3,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147285503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COPD Exacerbation Recognition Tool: Translation, Linguistic, and Cross-Cultural Validation.","authors":"Rainer Gloeckl, Ruth Tal-Singer, Peter Deussen, Russell Winwood, Tharishini Mohan, Megan Turner, Mohamed Hamouda, Mandeep Moore, Paul Jones","doi":"10.15326/jcopdf.2025.0745","DOIUrl":"10.15326/jcopdf.2025.0745","url":null,"abstract":"<p><strong>Background: </strong>The Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Recognition Tool (CERT) was developed to improve patients’ recognition of COPD exacerbations. This validation study concerned the cross-cultural and linguistic validation of 46 CERT translations across 25 countries and 6 continents.</p><p><strong>Methods: </strong>This study employed a rigorous, certified (International Organization for Standardization-17100) methodology. Dual forward translations for each language were developed by independent translators who were native speakers of the target language and then reconciled by a linguistic validation consultant (LVC). Independent linguists provided a back translation of the reconciled translation, which was reviewed by the LVC and project manager. Linguistic validation was performed for each language through cognitive debriefing interviews with at least 5 participants with COPD who were native speakers of the target language. These participants also reviewed 7 sets of images produced for different global regions to reflect patients from a diversity of cultures, countries, and religions, to determine if the images were representative of themselves and/or other people living with COPD. The images were amended as needed and reshown to the participants for approval.</p><p><strong>Results: </strong>The translations were found to be conceptually equivalent to the original CERT and harmonized with each other. Participants found the CERT easy to use and understand and confirmed that the images were representative of themselves and/or other people living with COPD.</p><p><strong>Conclusion: </strong>CERT translations were created using a patient-centric approach and appear to be easily understandable and valid across many languages and cultures.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":"147-157"},"PeriodicalIF":2.3,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}